Chennai, January 1st, 2026: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), through its subsidiary companies of Caplin Steriles Limited (CSL) and Caplin One Labs Limited (COL) has acquired 10 approved ANDAs for Injectable and Opthalmic products from a leading Multinational Generic product manufacturing company. These products’ addressable market was $ 473.2 million for the 12-month period ending August 2025.
Commenting on the acquisition, Mr. C.C. Paarthipan, Chairman said, “The U.S. market remains a key growth engine for the Company, and this acquisition meaningfully accelerates our strategy by expanding and strengthening our portfolio in the region. The acquired portfolio also includes select oncology injectables, which will be transferred to and commercialized from our new dedicated oncology facility in Kakkalur. In addition, we intend to progressively extend these products to key non-U.S. markets, including Mexico, Canada, the European Union, and Brazil.”